Paclitaxel-coated balloon angioplasty for recurrent arteriovenous fistula stenosis

Tan, Ru Yu; Pang, Suh Chien; Tng, Alvin Ren Kwang; Tan, Chieh Suai

doi:10.1016/j.kint.2021.04.041

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More pre-clinical testing of the SCBs in different animal models are also required especially for the AVF and PAD settings to look at pharmarcokinetics of the balloon. More data looking at the use of SCBs in different parts of the AVF circuit are warranted especially as we are beginning to realise that drug may have differential effects on different types of stenotic lesions (Tan et al 2021b ).…”

Section: Discussionmentioning

confidence: 99%

Utility of sirolimus coated balloons in the peripheral vasculature – a review of the current literature

et al. 2022

View full text Add to dashboard Cite

Sirolimus-coated balloons (SCB) have demonstrated much promise as an alternative drug eluting device to the existing paclitaxel coated balloon platforms for the treatment of peripheral arterial disease (PAD). They have been well tested pre-clinically and have demonstrated anti-restenotic effects as well as clinical safety in its use for treatment of coronary artery disease. The existing approved SCBs have thus far demonstrated good short-term patency (12-months) and did not exhibit any major adverse events or device related shortcomings in its use for treatment of PAD. There are several studies ongoing which aim to further investigate the efficacy of existing SCBs and establish a direct comparison of its outcomes compared with plain balloon angioplasty. Also, SCB utility to salvage failing arteriovenous fistulas for haemodialysis patients has also been explored. We review the current progress made in the establishment of SCB in the treatment of PAD as well as highlight ongoing studies investigating the role of SCB in various settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of sirolimus coated balloons in the peripheral vasculature – a review of the current literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The coating drug paclitaxel is highly lipophilic and can be rapidly absorbed by the tissue of vascular wall, reducing the drug loss caused by blood flow scouring and maintaining a high drug concentration in a short time, thus continuously exerting the effect of inhibiting intimal hyperplasia [ 14 ]. In addition, the rapid release and absorption of paclitaxel can inhibit the delay of vascular endothelialization and reduce re-revascularization [ 15 ]. In terms of safety, the liver and kidney functions of the two groups were comparable.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety Differences between Domestic Paclitaxel Drug‐Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral‐Popliteal Arteries Type IIA–C

Wei

Huang

Cui

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

The aim in this study was to investigate the efficacy and safety of domestic paclitaxel-coated balloon (DCB) and bare metal stent (BMS) in the treatment of Transatlantic Cooperative Organization Consensus II (ASC II) types A–C femoral-popliteal arteriosclerosis obliterans (ASO). A total of 103 patients with ASC II A–C femoropopliteal ASO, who received treatment in our hospital from March 2020 to March 2021, were retrospectively selected and divided into the DCB group (n = 56) and BMS group (n = 47), according to treatment methods. The general clinical data and surgical results were compared between the two groups. The patients were followed up, and the primary patency rate, restenosis rate, freedom from target lesion revascularization (f-TLR), and limb preservation rate were recorded. The liver and kidney functions before and after operation and the occurrence of major postoperative adverse events were recorded. The operation was successful in both groups. The minimum diameter of the DCB group was smaller than that of the BMS group after treatment P < 0.05 . At 6 and 12 months after operation, the Rutherford classification decreased and ABI index increased in both groups P < 0.05 , but there was no significant difference P > 0.05 . At 6 and 12 months after surgery, f-TLR was significantly higher in the DCB group than in the BMS group P < 0.05 ; at 12 months after surgery, the restenosis rate was lower in the DCB group than in the BMS group P < 0.05 . There was no significant difference in the primary patency rate and limb preservation rate at 6 and 12 months after operation between the two groups P > 0.05 . Before and after operation, there was no significant difference in liver and kidney function between the two groups P > 0.05 . Within 12 months after surgery, 1 patient in the DCB group developed puncture site hematoma 3 days after surgery, and 1 patient in the BMS group developed acute thrombosis 1 day after surgery, and no intervention-related deaths occurred. Domestic paclitaxel DCB can achieve better f-TLR and lower restenosis rate than BMS in the treatment of type II A–C femoral-popliteal artery ASO. Short-term and medium-term efficacy and safety are comparable to BMS.

show abstract

The authors reply:

Karunanithy

Robinson

Robson

2021

Kidney International

View full text Add to dashboard Cite

Paclitaxel-coated balloon angioplasty for recurrent arteriovenous fistula stenosis

Cited by 3 publications

References 5 publications

Utility of sirolimus coated balloons in the peripheral vasculature – a review of the current literature

Utility of sirolimus coated balloons in the peripheral vasculature – a review of the current literature

Efficacy and Safety Differences between Domestic Paclitaxel Drug‐Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral‐Popliteal Arteries Type IIA–C

The authors reply:

Contact Info

Product

Resources

About